Protalix Biotherapeutics ((PLX)) has held its Q3 earnings call. Read on for the main highlights of the call.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Protalix BioTherapeutics’ recent earnings call painted a picture of robust financial health and strategic advancements, despite some challenges. The company reported strong year-to-date revenue growth and a positive net income for Q3, backed by a solid cash position. However, the call also highlighted a slight dip in Q3 revenue, increased R&D expenses, and regulatory uncertainties in Europe concerning Elfabrio’s dosing regimen.
Strong Year-to-Date Revenue Growth
Protalix reported total revenues of $46.436 million for the first nine months of 2025, marking a 24% increase compared to the same period last year. This significant growth underscores the company’s successful sales strategies and market presence.
Advancement of PRX-115 Clinical Trial
The company is making headway with its PRX-115 candidate for uncontrolled gout, with preparations for a phase two clinical trial well underway. The IND was filed in October, and the trial is set to commence later this year, reflecting Protalix’s commitment to expanding its therapeutic pipeline.
Positive Net Income for Q3 2025
For the third quarter of 2025, Protalix reported a net income of approximately $2.4 million, translating to 3¢ per share, both basic and diluted. This positive financial outcome highlights the company’s effective cost management and revenue generation.
Strong Cash Position
As of September 30, 2025, Protalix maintained a strong cash position with $29.4 million in cash and cash equivalents and short-term bank deposits. This financial cushion is expected to support the company’s operations for at least the next twelve months.
Decrease in Q3 Revenue
Despite the overall positive financial performance, Protalix experienced a slight 1% decrease in Q3 2025 revenues, totaling $17.9 million. This dip was attributed to inventory fluctuations impacting quarterly sales.
Increased R&D Expenses
Research and development expenses rose significantly by 58% to $13.9 million for the nine months ended September 30, 2025. This increase reflects Protalix’s strategic investments in its pipeline, particularly in advancing clinical trials.
Pending CHMP Reexamination
Protalix is awaiting a decision in 2026 regarding the reexamination request submitted for the once every four weeks dosing regimen of Elfabrio in Europe. The company remains confident in its approved two-week regimen while navigating regulatory challenges.
Forward-Looking Guidance
Protalix’s forward-looking guidance remains optimistic, with expectations of continued revenue growth and strategic advancements. The company is focused on regulatory efforts with Chiesi and is poised to initiate the phase two trial for PRX-115 soon. Financially, Protalix is well-positioned with a net income of $2.4 million and substantial cash reserves to support its operations and strategic initiatives.
In conclusion, Protalix BioTherapeutics’ earnings call reflects a company in a strong financial position, with significant revenue growth and strategic advancements in its clinical pipeline. While challenges such as increased R&D expenses and regulatory uncertainties exist, Protalix remains optimistic about its future prospects and committed to its growth trajectory.